Envestnet Asset Management Inc. reduced its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 7.0% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 12,806 shares of the specialty pharmaceutical company’s stock after selling 971 shares during the period. Envestnet Asset Management Inc. owned 0.11% of ANI Pharmaceuticals worth $1,053,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in ANIP. New York State Common Retirement Fund increased its position in shares of ANI Pharmaceuticals by 3.4% during the first quarter. New York State Common Retirement Fund now owns 23,494 shares of the specialty pharmaceutical company’s stock valued at $1,657,000 after buying an additional 780 shares during the period. Wedge Capital Management L L P NC increased its position in shares of ANI Pharmaceuticals by 8.6% during the second quarter. Wedge Capital Management L L P NC now owns 7,386 shares of the specialty pharmaceutical company’s stock valued at $607,000 after buying an additional 586 shares during the period. Marshall Wace LLP bought a new stake in shares of ANI Pharmaceuticals during the first quarter valued at about $797,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ANI Pharmaceuticals by 237.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 559 shares during the period. Finally, Sawgrass Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals during the second quarter valued at about $517,000. Institutional investors and hedge funds own 70.76% of the company’s stock.
Shares of NASDAQ:ANIP traded up $4.17 during trading on Friday, reaching $76.65. 34,900 shares of the company traded hands, compared to its average volume of 152,099. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $873.62 million, a price-to-earnings ratio of 15.99 and a beta of 2.22. The business’s fifty day moving average is $72.13 and its 200-day moving average is $71.51. ANI Pharmaceuticals Inc has a 52-week low of $36.92 and a 52-week high of $86.96.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.18 by $0.26. The company had revenue of $54.36 million during the quarter, compared to the consensus estimate of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.13 earnings per share. On average, sell-side analysts predict that ANI Pharmaceuticals Inc will post 5.29 earnings per share for the current fiscal year.
Several research analysts have recently commented on ANIP shares. ValuEngine lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday. Guggenheim began coverage on ANI Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $76.00 target price for the company. Finally, BidaskClub lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $86.40.
In related news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $68.21, for a total transaction of $516,963.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 98,451 shares of company stock valued at $7,006,801. 24.70% of the stock is owned by corporate insiders.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Read More: What is the Russell 2000 Index?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.